Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors by Xinyue Han, Yingcui Chen, Hong Xie, Yuekai Zhang, Yu Cui, Yaping Guan, Weiwei Nie, Qi Xie, Jisheng Li, Baocheng Wang, Bicheng Zhang, Jun Wang

Subjects: Get full text

Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits by Mizuki Ida, Shiro Nakamori, Shinya Yamamoto, Seimi Watanabe, Kyoko Imanaka‐Yoshida, Masaki Ishida, Hajime Sakuma, Keiichi Yamanaka, Kaoru Dohi

Subjects: Get full text

Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer by Yuichi Ozawa, Yasuhiro Koh, Ryota Shibaki, Yuhei Harutani, Hiroaki Akamatsu, Atsushi Hayata, Takeya Sugimoto, Yuka Kitamura, Junya Fukuoka, Masanori Nakanishi, Nobuyuki Yamamoto

Subjects: Get full text

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study by Keiichiro Suminaga, Takashi Nomizo, Hironori Yoshida, Hiroaki Ozasa

Subjects: Get full text

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors by Ichiro Yamauchi, Daisuke Yabe

Subjects: Get full text

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops by Ayaka Kawaguchi, Hayato Tanaka, Hitoshi Tabuchi, Kei Nakai, Atsuki Fukushima

Subjects: Get full text

Six events that shaped antibody approvals in oncology by Suman Paul, Suman Paul, Shibin Zhou, Shibin Zhou

Subjects: Get full text

Combination of ataxia telangiectasia and Rad3-related inhibition with ablative radiotherapy remodels the tumor microenvironment and enhances immunotherapy response in lung cancer by Jenny Ling-Yu Chen, Chun-Kai Pan, Li-Cheng Lin, Yu-Sen Huang, Tsung-Hsuan Huang, Shu-Jyuan Yang, Sung-Hsin Kuo, Yu-Li Lin

Subjects: Get full text

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives by Bujnak AC, File B, Tewari KS

Subjects: Get full text

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial by Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai

Subjects: Get full text

Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherap... by Cheng-Wei Huang, Ruo-Han Tseng

Subjects: Get full text

A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy by Nao Kobayashi, Noriaki Sunaga, Masakiyo Yatomi, Ikuo Wakamatsu, Sohei Muto, Hayato Ikota, Rei Yamaguchi, Yoichi Ohtaki, Toshiteru Nagashima, Nobuteru Kubo, Tomomi Masuda, Yosuke Miura, Hiroaki Tsurumaki, Reiko Sakurai, Yasuhiko Koga, Takeshi Hisada, Toshitaka Maeno

Subjects: Get full text

Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma by Youjia Li, Kai Qu, Xiuli Li, Xin Yang, Kanghuai Zhang, Jiao Xie

Subjects: Get full text

Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1 by Coco Duizer, Moniek Salomons, Merel van Gogh, Sanne Gräve, Freke A. Schaafsma, Maaike J. Stok, Merel Sijbranda, Raghuvandhanan Kumarasamy Sivasamy, Rob J. L. Willems, Marcel R. de Zoete

Subjects: Get full text

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer by Huiping Qiang, Yue Wang, Yao Zhang, Jingwen Li, Lincheng Zhang, Huawei Du, Xuxinyi Ling, Shuhui Cao, Yan Zhou, Runbo Zhong, Hua Zhong

Subjects: Get full text

Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic chola... by Liu Song, Wang Qingdong, Yin Shunhang, Li Long, Zhao Guangsheng, Yu Guangji, Wang Dong

Subjects: Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

Subjects: Get full text

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors by Zixi Wu, Junbiao Zhang, Le Li, Zhihua Wang, Chunguang Yang

Subjects: Get full text

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics by B.E. Nelson, A. Naing, S. Fu, R.A. Sheth, R. Murthy, S. Piha-Paul

Subjects: Get full text

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal by Xinya Li, Zaiwei Song, Yixuan Chen, Jingjing Wu, Dan Jiang, Zhen Zhang, Zeyuan Wang, Rongsheng Zhao

Subjects: “…Immune checkpoint inhibitors…”
Get full text